Three U.S. pharmaceutical companies could expand after they received $93 million in funding from Rusnano, a Russian state technology firm, and various investors. Reuters reports that researchers with the three U.S. pharmaceutical businesses – Marinus Pharmaceuticals, Lithera and Regado Biosciences – will use the funds to study treatments for diseases such as epilepsy.
Rusnano officials noted that they also planned to make future investments in U.S. pharmaceutical companies. Around $760 million will be spent to fund research completed by U.S. healthcare and pharmaceutical firms, and Rusnano administrators said the American businesses could develop new drugs for the Russian market.
Tonix Pharmaceuticals, a specialty firm that develops treatments for central nervous system conditions, could also impact the U.S. economy over the next few years. Company leaders announced that they raised $1 million in gross proceeds from a private placement offering with venture capital firm Technology Partners. The additional funds will be used to help the firm develop new treatments, and the company could target new pharmaceutical professionals to provide extra assistance.
Content provided by executive search organization, MRINetwork.